Skip to main content
Top
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Deep Brain Stimulation | Research article

Association of polygenic risk score with response to deep brain stimulation in Parkinson’s disease

Authors: Esther Yoon, Sarah Ahmed, Ryan Li, Sara Bandres-Ciga, Cornelis Blauwendraat, Irene Dustin, Sonja Scholz, Mark Hallett, Debra Ehrlich

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Deep brain stimulation (DBS) is a well-established treatment option for select patients with Parkinson’s Disease (PD). However, response to DBS varies, therefore, the ability to predict who will have better outcomes can aid patient selection. Some PD-related monogenic mutations have been reported among factors that influence response to DBS. However, monogenic disease accounts for only a minority of patients with PD. The polygenic risk score (PRS) is an indication of cumulative genetic risk for disease. The PRS in PD has also been correlated with age of onset and symptom progression, but it is unknown whether correlations exist between PRS and DBS response. Here, we performed a pilot study to look for any such correlation.

Methods

We performed a retrospective analysis of 33 PD patients from the NIH PD Clinic and 13 patients from the Parkinson’s Progression Markers Initiative database who had genetic testing and underwent bilateral subthalamic nucleus DBS surgery and clinical follow-up. A PD-specific PRS was calculated for all 46 patients based on the 90 susceptibility variants identified in the latest PD genome-wide association study. We tested associations between PRS and pre- and post-surgery motor and cognitive measures using multiple regression analysis for up to two years after surgery.

Results

Changes in scores on the Beck Depression Inventory (BDI) were not correlated with PRS when derived from all susceptibility variants, however, when removing pathogenic and high-risk carriers from the calculation, higher PRS was significantly associated with greater reduction in BDI score at 3 months and with similar trend 24 months after DBS. PRS was not a significant predictor of Unified Parkinson’s Disease Rating Scale, Dementia Rating Scale, or phenomic and semantic fluency outcomes at 3- and 24-months after DBS surgery.

Conclusions

This exploratory study suggests that PRS may predict degree of improvement in depressive symptoms after DBS, though was not predictive of motor and other cognitive outcomes after DBS. Additionally, PRS may be most relevant in predicting DBS outcomes in patients lacking pathogenic or high-risk PD variants. However, this was a small preliminary study and response to DBS treatment is multifactorial, therefore, more standardized high-powered studies are needed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bari AA, Fasano A, Munhoz RP, Lozano AM. Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson’s disease. Expert Rev Neurother. 2015;15(10):1151–60.CrossRefPubMed Bari AA, Fasano A, Munhoz RP, Lozano AM. Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson’s disease. Expert Rev Neurother. 2015;15(10):1151–60.CrossRefPubMed
2.
go back to reference Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(S14):S290-304.CrossRefPubMed Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(S14):S290-304.CrossRefPubMed
3.
go back to reference Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease. JAMA Netw Open. 2019;2(2):e187800.CrossRefPubMedPubMedCentral Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease. JAMA Netw Open. 2019;2(2):e187800.CrossRefPubMedPubMedCentral
4.
go back to reference Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, et al. Parkinson disease and subthalamic nucleus deep brain stimulation: Cognitive effects in GBA mutation carriers. Ann Neurol. 2022;91(3):424–35.CrossRefPubMedPubMedCentral Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, et al. Parkinson disease and subthalamic nucleus deep brain stimulation: Cognitive effects in GBA mutation carriers. Ann Neurol. 2022;91(3):424–35.CrossRefPubMedPubMedCentral
5.
go back to reference Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. High frequency stimulation of the subthalamic nucleus is efficacious in parkin disease. J Neurol. 2005;252(2):208–11.CrossRefPubMed Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. High frequency stimulation of the subthalamic nucleus is efficacious in parkin disease. J Neurol. 2005;252(2):208–11.CrossRefPubMed
6.
go back to reference Lohmann E, Welter ML, Fraix V, Krack P, Lesage S, Laine S, et al. Are parkin patients particularly suited for deep-brain stimulation? Mov Disord. 2008;23(5):740–3.CrossRefPubMed Lohmann E, Welter ML, Fraix V, Krack P, Lesage S, Laine S, et al. Are parkin patients particularly suited for deep-brain stimulation? Mov Disord. 2008;23(5):740–3.CrossRefPubMed
7.
go back to reference Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(2):e187800.CrossRefPubMedPubMedCentral Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(2):e187800.CrossRefPubMedPubMedCentral
8.
go back to reference Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies. The Lancet Neurology. 2019;18(12):1091–102.CrossRefPubMedPubMedCentral Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies. The Lancet Neurology. 2019;18(12):1091–102.CrossRefPubMedPubMedCentral
9.
go back to reference Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol J-C, et al. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurol Genet. 2019;5(4):e348.CrossRefPubMedPubMedCentral Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol J-C, et al. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurol Genet. 2019;5(4):e348.CrossRefPubMedPubMedCentral
10.
go back to reference Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896–912. Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896–912.
12.
go back to reference Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015;4(1):7.CrossRefPubMedPubMedCentral Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015;4(1):7.CrossRefPubMedPubMedCentral
13.
go back to reference Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867–73.CrossRefPubMedPubMedCentral Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867–73.CrossRefPubMedPubMedCentral
14.
go back to reference The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467(7311):52–8.CrossRefPubMedCentral The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467(7311):52–8.CrossRefPubMedCentral
15.
go back to reference Bandrés-Ciga S, Price TR, Barrero FJ, Escamilla-Sevilla F, Pelegrina J, Arepalli S, et al. Genome-wide assessment of Parkinson’s disease in a southern Spanish population. Neurobiol Aging. 2016;45:213.e3-213.e9.CrossRefPubMed Bandrés-Ciga S, Price TR, Barrero FJ, Escamilla-Sevilla F, Pelegrina J, Arepalli S, et al. Genome-wide assessment of Parkinson’s disease in a southern Spanish population. Neurobiol Aging. 2016;45:213.e3-213.e9.CrossRefPubMed
16.
17.
go back to reference Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. Clinvar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(D1):D980-5.CrossRefPubMed Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. Clinvar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(D1):D980-5.CrossRefPubMed
18.
go back to reference Hentz JG, Mehta SH, Shill HA, Driver-Dunckley E, Beach TG, Adler CH. Simplified Conversion Method for Unified Parkinson’s Disease Rating Scale Motor Examinations. Mov Disord Off J Mov Disord Soc. 2015;30(14):1967–70.CrossRef Hentz JG, Mehta SH, Shill HA, Driver-Dunckley E, Beach TG, Adler CH. Simplified Conversion Method for Unified Parkinson’s Disease Rating Scale Motor Examinations. Mov Disord Off J Mov Disord Soc. 2015;30(14):1967–70.CrossRef
19.
go back to reference Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed
Metadata
Title
Association of polygenic risk score with response to deep brain stimulation in Parkinson’s disease
Authors
Esther Yoon
Sarah Ahmed
Ryan Li
Sara Bandres-Ciga
Cornelis Blauwendraat
Irene Dustin
Sonja Scholz
Mark Hallett
Debra Ehrlich
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03188-5

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue